Lupin has reported results for fourth quarter (Q4) and year ended March 31, 2024.
The company has reported over 3-fold jump in its net profit at Rs 384.08 crore for the quarter under review as compared to Rs 119.01 crore for the same quarter in the previous year. Total income of the company increased by 18.52% at Rs 3,427.22 crore for Q4FY24 as compared Rs 2,891.57 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 51.91% rise in its net profit at Rs 368.22 crore for fourth quarter ended March 31, 2024 as compared to Rs 242.39 crore for the same quarter in the previous year. Total income of the company increased by 11.70% at Rs 4,990.04 crore for Q4FY24 as compared Rs 4,467.35 crore for the corresponding quarter previous year.
For the year ended March 31, 2024, the company has reported over 5-fold jump in net profit at Rs 2,326.09 crore as compared to Rs 425.21 crore for the previous year. Total income of the company increased by 30.16% at Rs 14,773.23 crore for year under review as compared to Rs 11,350.09 crore for year ended March 31, 2023.
For the year ended March 31, 2024, on the consolidated basis, the company has reported over 4-fold jump in its net profit at Rs 1,935.57 crore as compared to Rs 447.69 crore for the previous year. Total income of the company increased by 20.44% at Rs 20,130.99 crore for year under review as compared to Rs 16,715.02 crore for year ended March 31, 2023.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1532.85 |
Dr. Reddys Lab | 5812.50 |
Cipla | 1403.90 |
Zydus Lifesciences | 1104.45 |
Lupin | 1661.90 |
View more.. |